Elevance Health Q3 Profit Climbs, Lifts FY26 Outlook, Sees Growth In FY27; Shares Up - Update

Elevance Health (ELV) reported Q3 net income of $1.365B, up 14.8% YoY, with EPS rising 17.9% to $6.27. Revenue increased 0.7% to $50.44B. The company raised FY26 EPS guidance to at least $22.00 and adjusted EPS to at least $29.00, and declared a $1.72 per share dividend. Shares gained 2.23% in pre-market trading.

Original reporting
Published Oct 21, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 12:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ELV
Bullish
high confidence
Mentioned
$ELV
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ELVBullishHigh
01

Why it matters

The earnings beat and guidance hike provide fresh, material information for traders, supporting a bullish stance.

02

Market read

The earnings surprise and guidance raise are likely to drive short‑term buying pressure in ELV and may lift the broader health‑insurance sector.

03

What to watch

Potential headwinds from Medicare Advantage enrollment declines could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Elevance Health reported Q3 net income of $1.365 B, EPS $6.27, and modest revenue growth, then lifted FY2026 and FY2027 guidance.

Company-level read

Ticker impact

$ELVBullishHigh confidence
Context

Elevance Health raised FY2026 EPS guidance to $22‑$20.10 and FY2027 EPS growth outlook, with Q3 earnings beating prior year.

Expected impact

likely upward pressure as investors price in higher earnings outlook

Evidence & confidence

Guidance lifts are material for a large‑cap health insurer and the stock already rose 2.2% pre‑market.

Market effects

Raises expectations for the health‑insurance sector, potentially boosting peers.

U.S. market sentiment may improve on earnings optimism.

Limited to U.S. insurers; no direct global macro effect.

Counterpoint

If the guidance raise is already priced in, the stock could face a short‑term pull‑back.

Key entities

  • Elevance Health Inc.

    U.S. health‑insurance provider (ticker ELV).

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$CVSMed

11 Medicare Advantage Insurers Sue CMS Over 2027 Star Ratings and Nearly $4 Billion in Payments

Eleven Medicare Advantage insurers, including CVS Health, Elevance Health, and Centene, sued the CMS over 2027 star ratings, claiming nearly $4 billion in potential losses. They argue CMS used unauthorized measures, citing a recent court ruling in Clover Health's favor. Higher ratings affect bonus payments and rebates. CMS is appealing the Clover decision and has not commented on the new lawsuits.

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.